Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.66 |
| ▸ | NPY1R | P25929 | 11/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.66 |
| ▸ | NPY2R | P49146 | 7/20 | 0.66 |
| ▸ | TFPI | P10646 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434681 | 0.95 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29442083 | 0.88 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29442111 | 0.88 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29442116 | 0.87 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30471426 | 0.87 | NPY4R (0.72) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29434605 | 0.87 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29442114 | 0.87 | NPY4R (0.73) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30202407 | 0.87 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL8997940 | 0.85 | TFPI (0.66) | TFPI | |
| SCHEMBL8998005 | 0.85 | TFPI (0.66) | TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | NPY4R 2058/4885NPY1R 1616/4885NPY5R 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.